Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Countrywide Study to Map Fake Drugs (India)

This article was originally published in PharmAsia News

Executive Summary

India's drug regulator has announced plans to collect 50,000 drug samples from around the country. The survey is designed to determine just how prevalent fake medications are in India's drug industry. Some estimates say fake drugs account for as little as 0.5 percent of India's drug market, while other projections put that figure as high as 30 percent. The European Union has also identified India as the biggest supplier of counterfeit drugs in the world, claiming over 30 percent of the fakes entering the EU come from India. These accusations are one of the reasons Indian drug manufacturers are also supporting the study. They say India's reputation for manufacturing counterfeit drugs is hurtful to their business. For them it is a win, win situation. If the study does not turn up widespread counterfeits, it will put to rest international anxieties. If the problem is discovered to be as severe as some believe, the study will go a long way toward ferreting out unsavory competition. The plan must still be approved by the ministry of health and family welfare before it can be put into effect. In the meantime, the drug controller has also proposed randomly visiting clinical testing sites to check human trials for authenticity. At the same time, legislation is in the works that would crack down on those who manufacture and distribute fake drugs. (Click here for more

You may also be interested in...

Pink Sheet Podcast: UK Clears COVID-19 Vaccine, FDA Pressure Increases; Biden’s FDA Commissioner

Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.

LivaNova Sells Surgical Heart Valve Business To Gyrus Capital For $73M

Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.

FDA Warning Letters Hit Two Firms For Slipshod Failure Investigations And Lax Approach to Cleaning

The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts